Scholarlink

<p>Stony corals (Scleractinia) harbor abundant toxins as part of their survival strategy, and these molecules also provide novel lead candidates for drug development. In this study, we present the first comprehensive investigation of toxin profiles of the understudied <i>Goniopora columna</i> through transcriptome analysis,&#xa0;which has expanded&#xa0;the biochemical diversity of marine organism derived toxins. Then, a novel Kunitz-like polypeptide, named GcKuz1, which exhibits therapeutic potential for thrombosis was selected for functional studies and mechanistic investigation. In vitro experiments revealed that GcKuz1, at 2–16 μM, delayed plasma recalcification time and activated partial thromboplastin time without affecting prothrombin time. In murine models, GcKuz1, at 1–4 mg/kg dosage, significantly inhibited the FeCl<sub>3</sub>-induced carotid artery thrombosis and the carrageenan-induced mouse tail thrombosis. Moreover, GcKuz1 effectively attenuated thrombo-inflammation and cerebral tissue destruction, as well as restored blood–brain barrier integrity, in the transient middle cerebral artery occlusion model. Through enzyme kinetics assays and surface plasmon resonance (SPR) verification, GcKuz1 was shown to strongly inhibit the enzyme activity of plasma kallikrein (PKa) and FXIIa, two key factors involved in the contact-kinin pathway, via direct interaction, thereby exerting anticoagulation effects without impairing hemostasis. Notably, safety evaluation highlights the low toxicity, minimal hemolytic activity and reduced bleeding risk of GcKuz1, which underline its clinical availability. In conclusion, as a novel coral-derived protease inhibitor of FXIIa and PK, GcKuz1 offers potential therapeutic benefits in the treatment thrombosis-related cardiovascular diseases treatment by suppressing inflammation and preventing thrombus formation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel polypeptide from stony coral Goniopora columna inhibits thrombosis by interfering with the contact-kinin pathway

  • 期刊论文

  • 发表日期：

    2025年6月4日

查看全文
  • Qian Chen,
  • Congshuang Deng,
  • Xiaoshan Huang,
  • Kaixun Cao,
  • Hanbin Chen,
  • Yang Chen,
  • Mehwish Khalid,
  • Qiuyue Xu,
  • Qiumin Lu,
  • Ziyi Wang,
  • Aili Wang,
  • Ren Lai

摘要

Stony corals (Scleractinia) harbor abundant toxins as part of their survival strategy, and these molecules also provide novel lead candidates for drug development. In this study, we present the first comprehensive investigation of toxin profiles of the understudied Goniopora columna through transcriptome analysis, which has expanded the biochemical diversity of marine organism derived toxins. Then, a novel Kunitz-like polypeptide, named GcKuz1, which exhibits therapeutic potential for thrombosis was selected for functional studies and mechanistic investigation. In vitro experiments revealed that GcKuz1, at 2–16 μM, delayed plasma recalcification time and activated partial thromboplastin time without affecting prothrombin time. In murine models, GcKuz1, at 1–4 mg/kg dosage, significantly inhibited the FeCl3-induced carotid artery thrombosis and the carrageenan-induced mouse tail thrombosis. Moreover, GcKuz1 effectively attenuated thrombo-inflammation and cerebral tissue destruction, as well as restored blood–brain barrier integrity, in the transient middle cerebral artery occlusion model. Through enzyme kinetics assays and surface plasmon resonance (SPR) verification, GcKuz1 was shown to strongly inhibit the enzyme activity of plasma kallikrein (PKa) and FXIIa, two key factors involved in the contact-kinin pathway, via direct interaction, thereby exerting anticoagulation effects without impairing hemostasis. Notably, safety evaluation highlights the low toxicity, minimal hemolytic activity and reduced bleeding risk of GcKuz1, which underline its clinical availability. In conclusion, as a novel coral-derived protease inhibitor of FXIIa and PK, GcKuz1 offers potential therapeutic benefits in the treatment thrombosis-related cardiovascular diseases treatment by suppressing inflammation and preventing thrombus formation.